Finance analyst: Eli Lilly deals hard blow to Novo Nordisk with new data

While many Danish analysts were not overly concerned by Eli Lilly's novel data for tirzepatide as a rival to Novo Nordisk's semaglutide, financial analyst Jefferies sees the new data as a considerable threat against Novo Nordisk's market shares.

Photo: Darron Cummings/AP/Ritzau Scanpix

US investment banking company and financial analyst Jefferies views data from US pharmaceutical company Eli Lilly's recent studies with tirzepatide up against Danish firm Novo Nordisk's semaglutide as highly convincing. In-house analyst Peter Welford thinks Novo Nordisk's salespeople will have a hard time contesting tirzepatide's superior effect, since the new data comes from a direct comparison study, known as a head-to-head.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs